drugset
drugset / Trial / NCT00356408

Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease

NCT00356408 ↗

Phase 3 Completed 106 enrolled UCB Pharma
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label extension study designed to measure the safety, efficacy, and corticosteroid-sparing effect of certolizumab pegol (CDP870) in patients with moderate to severe Crohn's disease previously enrolled in C87059 (COSPAR I, NCT00349752).

Timeline

Start
2007-01
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Certolizumab Pegol Protein / enzyme biologic 400 mg Other

Indications

Crohn disease